Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Abstract 665: MEN1703/SEL24 exhibits promising antitumoral activity in preclinical models of myelofibrosis both as single agent and combined with ruxolitinib

Maria Luisa Iannitto, Diego Bisignano, Sonia Zicari, Francesco Belli, Alessio Fiascarelli, Simone Talucci, Giuseppe Merlino, Vittoria Nicolis di Robilant, Clelia Irrissuto, Mario Bigioni, Alessandro Bressan, Daniela Bellarosa, Monica Binaschi

Cancer Res (2024) 84 (6_Supplement): 665.

https://doi.org/10.1158/1538-7445.AM2024-665

Published: 22 March 2024

View article titled, Abstract 665: MEN1703/SEL24 exhibits promising antitumoral activity in preclinical models of myelofibrosis both as single agent and combined with ruxolitinib

Journal Articles

Abstract CT073: Efficacy of novel oral SERD elacestrant in fulvestrant-refractory hormone receptor-positive (HR+) breast cancer: a translational investigation

Cancer Res (2023) 83 (8_Supplement): CT073.

https://doi.org/10.1158/1538-7445.AM2023-CT073

Published: 14 April 2023

View article titled, Abstract CT073: Efficacy of novel oral SERD elacestrant in fulvestrant-refractory hormone receptor-positive (HR+) breast cancer: a translational investigation

Journal Articles

Abstract 2849: The oral SERD Elacestrant in combination with the PI3K inhibitor MEN1611 inhibits tumor growth in ER+/HER2- breast cancer in vitro and in PDX models

Giuseppe Merlino, Alessio Fiascarelli, Simone Talucci, Patrizia Tunici, Mario Bigioni, Alessandro Bressan, Monica Binaschi

Cancer Res (2023) 83 (7_Supplement): 2849.

https://doi.org/10.1158/1538-7445.AM2023-2849

Published: 04 April 2023

View article titled, Abstract 2849: The oral SERD Elacestrant in combination with the PI3K inhibitor MEN1611 inhibits tumor growth in ER+/HER2- breast cancer in vitro and in PDX models

Journal Articles

Abstract 1170: MEN1112/OBT357, a first-in-class humanized de-fucosylated monoclonal antibody targeting CD157 positive cells in acute myeloid leukemia and myelodysplastic syndrome

Corrado Carrisi, Daniela Bellarosa, Diego Bisignano, Adriano Venditti, Francesco Buccisano, Giuseppe Sconocchia, Andrea Coppola, Anna Aureli, Alessio Fiascarelli, Alessandro Bressan, Simone Baldini, Andrea Pellacani, Monica Binaschi

Cancer Res (2021) 81 (13_Supplement): 1170.

https://doi.org/10.1158/1538-7445.AM2021-1170

Published: 01 July 2021

View article titled, Abstract 1170: MEN1112/OBT357, a first-in-class humanized de-fucosylated monoclonal antibody targeting CD157 positive cells in acute myeloid leukemia and myelodysplastic syndrome

Journal Articles

Abstract 1376: Dosing frequency/PD/efficacy relationship of MEN1611 in HER2 amplified, PIK3CA mutated, and refractory to Trastuzumab xenograft model of breast cancer

Alessio Fiascarelli, Giuseppe Merlino, Stefania Capano, Alessandro Bressan, Mario Bigioni, Andrea Pellacani, Monica Binaschi, Massimiliano Salerno

Cancer Res (2021) 81 (13_Supplement): 1376.

https://doi.org/10.1158/1538-7445.AM2021-1376

Published: 01 July 2021

View article titled, Abstract 1376: Dosing frequency/PD/efficacy relationship of MEN1611 in HER2 amplified, PIK3CA mutated, and refractory to Trastuzumab xenograft model of breast cancer

Journal Articles

Abstract PS18-13: Men1611 is a pi3k α/β selective and δ sparing inhibitor with long-lasting antitumor activity in different genetic backgrounds of pik3ca mutant breast cancer models

Alessio Fiascarelli, Corrado Carrisi, Giuseppe Merlino, Stefania Capano, Diego Bisignano, Simone Talucci, Alessandro Bressan, Daniele Bellarosa, Mario Bigioni, Maurizio Scaltriti, Joaquin Arribas, Andrea Pellacani, Massimiliano Salerno, Monica Binaschi

Cancer Res (2021) 81 (4_Supplement): PS18-13.

https://doi.org/10.1158/1538-7445.SABCS20-PS18-13

Published: 15 February 2021

View article titled, Abstract PS18-13: Men1611 is a pi3k α/β selective and δ sparing inhibitor with long-lasting antitumor activity in different genetic backgrounds of pik3ca mutant breast cancer models

Journal Articles

Abstract PS18-26: Men1611 promotes immune activating myeloid cell polarization

Stefania Capano, Alessandro Paoli, Alessio Fiascarelli, Andrea Massimiliano Tomirotti, Mario Bigioni, Alessandro Bressan, Daniela Bellarosa, Massimiliano Salerno, Monica Binaschi

Cancer Res (2021) 81 (4_Supplement): PS18-26.

https://doi.org/10.1158/1538-7445.SABCS20-PS18-26

Published: 15 February 2021

View article titled, Abstract PS18-26: Men1611 promotes immune activating myeloid cell polarization

Journal Articles

Abstract 2160: MEN1611, a novel α-selective PI3K inhibitor in solid tumors

Giuseppe Merlino, Alessio Fiascarelli, Mario Bigioni, Alessandro Bressan, Clelia Irrissuto, Andrea Pellacani, Maurizio Scaltriti, Monica Binaschi

Cancer Res (2018) 78 (13_Supplement): 2160.

https://doi.org/10.1158/1538-7445.AM2018-2160

Published: 01 July 2018

View article titled, Abstract 2160: MEN1611, a novel α-selective PI3K inhibitor in solid tumors

Journal Articles

Abstract 2145: The role of MEN1611, a class I PI3-kinases (PI3Ks) inhibitor, in reprogramming the pro-tumoral inflammatory environment

Stefania Capano, Alessio Fiascarelli, Andrea M Tomirotti, Mario Bigioni, Alessandro Bressan, Daniela Bellarosa, Andrea Pellacani, Monica Binaschi

Cancer Res (2018) 78 (13_Supplement): 2145.

https://doi.org/10.1158/1538-7445.AM2018-2145

Published: 01 July 2018

View article titled, Abstract 2145: The role of MEN1611, a class I PI3-kinases (PI3Ks) inhibitor, in reprogramming the pro-tumoral inflammatory environment

Journal Articles

Abstract 1701: The novel anti-CD205 antibody drug conjugate (ADC) MEN1309 shows strong antitumoral activity in diffuse large B cell lymphoma (DLBCL)

Eugenio Gaudio, Chiara Tarantelli, Francesca Guidetti, Maurilio Ponzoni, Roberta Pittau Bordone, Alessio Fiascarelli, Andrea Rinaldi, Ivo Kwee, Afua Adjeiwaa Mensah, Anastasios Stathis, Davide Rossi, Georg Stussi, Emanuele Zucca, Giuseppe Merlino, Mario Bigioni, Monica Binaschi, Francesco Bertoni

Cancer Res (2017) 77 (13_Supplement): 1701.

https://doi.org/10.1158/1538-7445.AM2017-1701

Published: 01 July 2017

View article titled, Abstract 1701: The novel anti-CD205 antibody drug conjugate (ADC) MEN1309 shows strong antitumoral activity in diffuse large B cell lymphoma (DLBCL)

Journal Articles

Abstract 2630: MEN1309, a novel antibody drug conjugate (ADC) targeting Ly75 antigen, induces complete responses in several xenografts of solid tumors

Mario Bigioni, Giuseppe Merlino, Cristina Bernadó Morales, Rossana Bugianesi, Attilio Crea, Rosanna Manno, Joaquin Arribas, Rachel Dusek, Nickolas Attanasio, Keith Wilson, Christian Rohlff, Monica Binaschi

Cancer Res (2017) 77 (13_Supplement): 2630.

https://doi.org/10.1158/1538-7445.AM2017-2630

Published: 01 July 2017

View article titled, Abstract 2630: MEN1309, a novel antibody drug conjugate (ADC) targeting Ly75 antigen, induces complete responses in several xenografts of solid tumors

Journal Articles

Abstract 3646: Characterization of the novel antibody drug conjugate MEN1309 and its target antigen Ly75

Alessandro Bressan, Alessio Fiascarelli, Giuseppe Merlino, Corrado Carrisi, Daniela Bellarosa, Rachel Dusek, Rahel Awdew, Sudha Swaminathan, Arnima Bisht, To Uyen T. Do, San Lin Lou, Dee Aud, Jonathan Terrett, Keith Wilson, Christian Rohlff, Monica Binaschi

Cancer Res (2017) 77 (13_Supplement): 3646.

https://doi.org/10.1158/1538-7445.AM2017-3646

Published: 01 July 2017

View article titled, Abstract 3646: Characterization of the novel antibody drug conjugate MEN1309 and its target antigen Ly75

Journal Articles

Marked efficacy of the novel camptothecin MEN4901/T-0128 in orthotopic and metastatic human tumor xenograft models

Takayuki Kawaguchi, Xiaoming Li, Mario Bigioni, Kohji Oda, Satoshi Okuno, Masatoshi Kakushima, Monica Binaschi, Fabio Animati, Shigeo Yagi, Robert M. Hoffman

Cancer Res (2006) 66 (8_Supplement): 264.

Published: 15 April 2006

View article titled, Marked efficacy of the novel camptothecin MEN4901/T-0128 in orthotopic and metastatic human tumor xenograft models

Journal Articles

In Vivo Site Specificity and Human Isoenzyme Selectivity of Two Topoisomerase II-poisoning Anthracyclines

Monica Binaschi, Rosalba Farinosi, M. Evelina Borgnetto, Giovanni Capranico

Cancer Res (2000) 60 (14): 3770–3776.

Published: 15 July 2000

View article titled, In Vivo Site Specificity and Human Isoenzyme Selectivity of Two Topoisomerase II-poisoning Anthracyclines

Journal Articles

Tethering a Type IB Topoisomerase to a DNA Site by Enzyme Fusion to a Heterologous Site-selective DNA-binding Protein Domain

Giovanni Luca Beretta, Monica Binaschi, Emanuela Zagni, Luisa Capuani, Giovanni Capranico

Cancer Res (1999) 59 (15): 3689–3697.

Published: 01 August 1999

View article titled, Tethering a Type IB Topoisomerase to a DNA Site by Enzyme Fusion to a Heterologous Site-selective DNA-binding Protein Domain

Journal Articles

Human DNA Topoisomerase IIα-dependent DNA Cleavage and Yeast Cell Killing by Anthracycline Analogues

Monica Binaschi, Rosalba Farinosi, Caroline A. Austin, L. Mark Fisher, Franco Zunino, Giovanni Capranico

Cancer Res (1998) 58 (9): 1886–1892.

Published: 01 May 1998

View article titled, Human DNA Topoisomerase IIα-dependent DNA Cleavage and Yeast Cell Killing by Anthracycline Analogues

Journal Articles

Irreversible and Reversible Topoisomerase II DNA Cleavage Stimulated by Clerocidin: Sequence Specificity and Structural Drug Determinants

Monica Binaschi, Giuseppe Zagotto, Manlio Palumbo, Franco Zunino, Rosalba Farinosi, Giovanni Capranico

Cancer Res (1997) 57 (9): 1710–1716.

Published: 01 May 1997

View article titled, Irreversible and Reversible Topoisomerase II DNA Cleavage Stimulated by Clerocidin: Sequence Specificity and Structural Drug Determinants

Update search

NARROW

Format

Journal

Article Type

Issue Section

Date

Availability

Abstract 665: MEN1703/SEL24 exhibits promising antitumoral activity in preclinical models of myelofibrosis both as single agent and combined with ruxolitinib

Abstract CT073: Efficacy of novel oral SERD elacestrant in fulvestrant-refractory hormone receptor-positive (HR+) breast cancer: a translational investigation

Abstract 2849: The oral SERD Elacestrant in combination with the PI3K inhibitor MEN1611 inhibits tumor growth in ER+/HER2- breast cancer in vitro and in PDX models

Abstract 1170: MEN1112/OBT357, a first-in-class humanized de-fucosylated monoclonal antibody targeting CD157 positive cells in acute myeloid leukemia and myelodysplastic syndrome

Abstract 1376: Dosing frequency/PD/efficacy relationship of MEN1611 in HER2 amplified, PIK3CA mutated, and refractory to Trastuzumab xenograft model of breast cancer

Abstract PS18-13: Men1611 is a pi3k α/β selective and δ sparing inhibitor with long-lasting antitumor activity in different genetic backgrounds of pik3ca mutant breast cancer models

Abstract PS18-26: Men1611 promotes immune activating myeloid cell polarization

Abstract 2160: MEN1611, a novel α-selective PI3K inhibitor in solid tumors

Abstract 2145: The role of MEN1611, a class I PI3-kinases (PI3Ks) inhibitor, in reprogramming the pro-tumoral inflammatory environment

Abstract 1701: The novel anti-CD205 antibody drug conjugate (ADC) MEN1309 shows strong antitumoral activity in diffuse large B cell lymphoma (DLBCL)

Abstract 2630: MEN1309, a novel antibody drug conjugate (ADC) targeting Ly75 antigen, induces complete responses in several xenografts of solid tumors

Abstract 3646: Characterization of the novel antibody drug conjugate MEN1309 and its target antigen Ly75

Marked efficacy of the novel camptothecin MEN4901/T-0128 in orthotopic and metastatic human tumor xenograft models

In Vivo Site Specificity and Human Isoenzyme Selectivity of Two Topoisomerase II-poisoning Anthracyclines

Tethering a Type IB Topoisomerase to a DNA Site by Enzyme Fusion to a Heterologous Site-selective DNA-binding Protein Domain

Human DNA Topoisomerase IIα-dependent DNA Cleavage and Yeast Cell Killing by Anthracycline Analogues

Irreversible and Reversible Topoisomerase II DNA Cleavage Stimulated by Clerocidin: Sequence Specificity and Structural Drug Determinants

Email alerts

AACR Journals

Resources

AACR Journals
on Social Media

Update search

Email alerts

AACR Journals

Resources

AACR Journals on Social Media

This Feature Is Available To Subscribers Only

AACR Journals
on Social Media